Vertex Pharmaceuticals

By person

36 insiders · 1,897 transactions

31.8×

Reshma Kewalramani holds 31.8 times base salary in stock. $51.01M of shares against $1.60M in salary for 2025.

Salary from the company's own proxy. The shares are what Reshma Kewalramani last reported holding, valued at $519.00, the price Common Stock was last bought or sold at on the open market here, on 2 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

LEIDEN JEFFREY M

Executive Chairman

—

$498.46M (156) scheduled

−$498.46M

34,797

$18.06M

−86.8%

Sachdev Amit

EVP Chief Patient & Ext Af Off

—

$128.86M (187) scheduled

−$128.86M

66,512

$34.52M

−18.1%

Arbuckle Stuart A

EVP, COO

—

$114.46M (206) scheduled

−$114.46M

97,921

$50.82M

−39.9%

ALTSHULER DAVID

EVP, Chief Scientific Officer

—

$88.19M (209) scheduled

−$88.19M

34,477

$17.89M

−64.0%

Kewalramani Reshma

CEO & President

$5.85M (4)

$80.66M (75) scheduled

−$74.81M

98,278

$51.01M

+964.3%

SMITH IAN F

EVP, COO

—

$67.00M (49) scheduled

−$67.00M

46,699

$24.24M

−60.3%

Parini Michael

EVP, Chief Adm, Leg & BD Off

—

$45.43M (168) scheduled

−$45.43M

30,837

$16.00M

+109.9%

Silva Paul M

SVP & Chief Accounting Officer

—

$35.17M (136) scheduled

−$35.17M

9,884

$5.13M

−32.2%

SACHS BRUCE I

Director

$8.18M (6)

$38.25M (28) scheduled

−$30.08M

39,000

$20.24M

+175.6%

Bozic Carmen

EVP and CMO

—

$30.00M (22) scheduled

−$30.00M

15,337

$7.96M

+631.4%

Chodakewitz Jeffrey

EVP

—

$27.57M (71) scheduled

−$27.57M

69,663

$36.16M

−38.1%

WAGNER CHARLES F JR

EVP, CO & FO

—

$24.25M (48) scheduled

−$24.25M

47,042

$24.41M

+6,535%

Tatsis Ourania

EVP, Chief Reg. & Quality Off.

—

$21.35M (93) scheduled

−$21.35M

53,572

$27.80M

+529.0%

Lee Yuchun

Director

—

$18.69M (138) scheduled

−$18.69M

1,875

$973.13K

−52.9%

MCGLYNN MARGARET G

Director

—

$14.52M (14) scheduled

−$14.52M

178

$92.38K

−95.7%

Kearney Terrence C

Director

—

$13.99M (7) scheduled

−$13.99M

6,536

$3.39M

+47.2%

Bhatia Sangeeta N.

Director

—

$12.67M (63) scheduled

−$12.67M

4,924

$2.56M

+67.4%

Atkinson Edward Morrow III

EVP, Chief Technical Ops. Off.

—

$11.60M (13) scheduled

−$11.60M

18,432

$9.57M

+32.8%

YOUNG WILLIAM D

Director

—

$10.94M (8) scheduled

−$10.94M

9,311

$4.83M

+216.6%

Sanna Bastiano

EVP, Cell & Genetic Therapies

—

$10.54M (63) scheduled

−$10.54M

32,038

$16.63M

+49.6%

BOGER JOSHUA S

Director

—

$9.22M (54) scheduled

−$9.22M

284,088

$147.44M

+0.8%

Biller Jonathan

EVP and Chief Legal Officer

—

$7.81M (12) scheduled

−$7.81M

13,659

$7.09M

—

McKechnie Duncan

EVP, Chief Commercial Officer

—

$5.66M (5) scheduled

−$5.66M

11,001

$5.71M

−32.1%

Ambrose Kristen

SVP & Chief Accounting Officer

—

$4.93M (19) scheduled

−$4.93M

11,624

$6.03M

+733.9%

Liu Joy

EVP and Chief Legal Officer

—

$4.73M (31)

−$4.73M

19,131

$9.93M

−31.2%

Bunnage Mark E.

EVP, Chief Scientific Officer

—

$3.00M (5) scheduled

−$3.00M

7,284

$3.78M

−54.7%

CARNEY LLOYD

Director

—

$865.41K (3)

−$865.41K

6,315

$3.28M

—

Graney Thomas

Chief Financial Officer

—

$324.44K (2)

−$324.44K

12,430

$6.45M

+5,628%

ULLIAN ELAINE

Director

—

12,195

$6.33M

+48.6%

van Grunsven Jasper

EVP, CP and NPPO

—

8,682

$4.51M

—

Garber Alan M

Director

—

7,344

$3.81M

—

MCKENZIE DIANA

Director

—

2,378

$1.23M

—

Thornberry Nancy

Director

—

2,109

$1.09M

—

Upadhyay Suketu

Director

—

1,558

$808.60K

—

Schneider Jennifer

Director

—

1,394

$723.49K

—

Lagarde Michel

Director

—

1,132

$587.51K

—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

By person

Individual transactions

What was left out